The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome-Reference-Cited by-同舟云学术

The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome

Published:2018-06-01 Issue:2 Volume:171 Page:273-282
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Arias-Pulido H.^ORCID,Cimino-Mathews A.,Chaher N.,Qualls C.,Joste N.,Colpaert C.,Marotti J. D.,Foisey M.,Prossnitz E. R.,Emens L. A.,Fiering S.

Funder

National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s10549-018-4834-7/fulltext.html

Reference32 articles.

1. Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH (2005) Trends in Inflammatory Breast Carcinoma Incidence and Survival: The Surveillance, Epidemiology, and End Results Program at the National Cancer Institute. J Natl Cancer Inst 97(13):966–975. https://doi.org/10.1093/jnci/dji172

2. Dawood S, Lei X, Dent R, Gupta S, Sirohi B, Cortes J, Cristofanilli M, Buchholz T, Gonzalez-Angulo AM (2014) Survival of women with inflammatory breast cancer: a large population-based study. Ann Oncol 25(6):1143–1151. https://doi.org/10.1093/annonc/mdu121

3. Pierga J-Y, Petit T, Delozier T, Ferrero J-M, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, Charafe-Jauffret E, Pavlyuk M, Kraemer S, Bidard F-C, Viens P (2012) Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncol 13(4):375–384. https://doi.org/10.1016/S1470-2045(12)70049-9

4. Schlichting JA, Soliman AS, Schairer C, Schottenfeld D, Merajver SD (2012) Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990–2008. Breast Cancer Res Treat 134(3):1257–1268. https://doi.org/10.1007/s10549-012-2133-2

5. Dawood S, Ueno N, Valero V, Woodward W, Buchholz T, Hortobagyi G, Gonzalez-Angulo A, Cristofanilli M (2011) Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer 117(9):1819–1826

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PD-L1 Expression in Colorectal Carcinoma Correlates with the Immune Microenvironment;Journal of Gastrointestinal Cancer;2024-03-26

2. Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics;Frontiers in Immunology;2024-03-12

3. Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy;International Journal of Molecular Sciences;2024-02-23

4. Deciphering the molecular biology of inflammatory breast cancer through molecular characterization of patient samples and preclinical models;International Review of Cell and Molecular Biology;2024

5. Correlation of an immune-related 8-gene panel with pathologic response to neoadjuvant chemotherapy in patients with primary breast cancers;Translational Oncology;2023-12